32 results on '"Klatt, Nichole R"'
Search Results
2. The vaginal microbiome and HIV transmission dynamics
- Author
-
Cherenack, Emily M., Broedlow, Courtney A., and Klatt, Nichole R.
- Published
- 2024
- Full Text
- View/download PDF
3. Accommodating multiple potential normalizations in microbiome associations studies
- Author
-
Song, Hoseung, Ling, Wodan, Zhao, Ni, Plantinga, Anna M., Broedlow, Courtney A., Klatt, Nichole R., Hensley-McBain, Tiffany, and Wu, Michael C.
- Published
- 2023
- Full Text
- View/download PDF
4. Mass spectrometry analysis of gut tissue in acute SIV-infection in rhesus macaques identifies early proteome alterations preceding the interferon inflammatory response
- Author
-
Berard, A. R., Hensley-McBain, T., Noël-Romas, L., Birse, K., Abou, M., Westmacott, G., McCorrister, S., Smedley, J., Klatt, Nichole R., and Burgener, Adam D.
- Published
- 2023
- Full Text
- View/download PDF
5. Assessing Intravaginal Practices in HIV Prevention Research: Development and Validation of an Intravaginal Practices Questionnaire
- Author
-
Rodriguez, Violeta J., Salazar, Ana S., Cherenack, Emily M., Klatt, Nichole R., Jones, Deborah L., and Alcaide, Maria L.
- Published
- 2023
- Full Text
- View/download PDF
6. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial
- Author
-
Anderson, Blake, Atwater, Riannon C, Avula, Nandini, Beckman, Kenny B, Belani, Hrishikesh K, Boulware, David R, Bramante, Carolyn T, Brea, Jannis, Broedlow, Courtney A, Buse, John B, Campora, Paula, Challa, Anup, Charles, Jill, Christensen, Grace, Christiansen, Theresa, Cohen, Ken, Connelly, Bo, Datta, Srijani, Deng, Nikita, Dunn, Alex T, Erickson, Spencer M, Fairbairn, Faith M, Fenno, Sarah L, Fraser, Daniel J, Fricton, Regina D, Griffiths, Gwen, Hagen, Aubrey A, Hartman, Katrina M, Hendrickson, Audrey F, Huling, Jared D, Ingraham, Nicholas E, Jeng, Arthur C, Johnson, Darrell M, Karger, Amy B, Klatt, Nichole R, Kuehl, Erik A, LaBar, Derek D, Lee, Samuel, Liebovitz, David M, Lindberg, Sarah, Luke, Darlette G, Machicado, Rosario, Mohamud, Zeinab, Murray, Thomas A, Ngonyama, Rumbidzai, Nicklas, Jacinda M, Odde, David J, Parrens, Elliott, Parra, Daniela, Patel, Barkha, Proper, Jennifer L, Pullen, Matthew F, Puskarich, Michael A, Rao, Via, Reddy, Neha V, Reddy, Naveen, Rypka, Katelyn J, Saveraid, Hanna G, Seloadji, Paula, Shahriar, Arman, Sherwood, Nancy, Siegart, Jamie L, Siegel, Lianne K, Simmons, Lucas, Sinelli, Isabella, Singh, Palak, Snyder, Andrew, Stauffer, Maxwell T, Thompson, Jennifer, Tignanelli, Christopher J, Tople, Tannon L, Tordsen, Walker J, Watson, Ray HB, Wu, Beiqing, Zaman, Adnin, Zolik, Madeline R, Zinkl, Lena, Anderson, Blake J, Thompson, Jennifer L, Pullen, Matthew, Wirtz, Esteban Lemus, Sherwood, Nancy E, Lindberg, Sarah M, Beckman, Kenneth B, Rose, Michael R, Mehta, Tanvi, Griffiths, Gwendolyn, and Bhat, Neeta S
- Published
- 2023
- Full Text
- View/download PDF
7. A Syndemic Approach to Explore Factors Associated with Bacterial Vaginosis
- Author
-
Salazar, Ana S., Nogueira, Nicholas F., Rodriguez, Violeta J., Mantero, Alejandro, Cherenack, Emily M., Raccamarich, Patricia, Maddalon, Marissa, Brophy, Theodora, Montgomerie, Emily, Klatt, Nichole R., Jones, Deborah L., and Alcaide, Maria L.
- Published
- 2022
- Full Text
- View/download PDF
8. Upregulation of IFN-stimulated genes persists beyond the transitory broad immunologic changes of acute HIV-1 infection
- Author
-
Mackelprang, Romel D., Filali-Mouhim, Abdelali, Richardson, Brian, Lefebvre, Francois, Katabira, Elly, Ronald, Allan, Gray, Glenda, Cohen, Kristen W., Klatt, Nichole R., Pecor, Tiffany, Celum, Connie, McElrath, M. Juliana, Hughes, Sean M., Hladik, Florian, Cameron, Mark J., and Lingappa, Jairam R.
- Published
- 2023
- Full Text
- View/download PDF
9. Gender Identity Stigma in Transgender Women Is Higher After Gender-Affirming Vaginoplasty.
- Author
-
Fein, Lydia A., Barnett, Rebecca, Liu, Tianhao, Potter, JoNell E., Klatt, Nichole R., Alcaide, Maria L., and Jones, Deborah L.
- Published
- 2024
- Full Text
- View/download PDF
10. Natural killer like B cells are a distinct but infrequent innate immune cell subset modulated by SIV infection of rhesus macaques.
- Author
-
Manickam, Cordelia, Upadhyay, Amit A., Woolley, Griffin, Kroll, Kyle W., Terry, Karen, Broedlow, Courtney A., Klatt, Nichole R., Bosinger, Steven E., and Reeves, R. Keith
- Subjects
KILLER cells ,B cells ,RHESUS monkeys ,NATURAL immunity ,TRAFFIC signs & signals ,CELL imaging ,RNA sequencing ,B cell receptors ,ORAL mucosa - Abstract
Natural killer-like B (NKB) cells are unique innate immune cells expressing both natural killer (NK) and B cell receptors. As first responders to infection, they secrete IL-18 to induce a critical cascade of innate and adaptive immune cell infiltration and activation. However, limited research exists on the role of NKB cells in homeostasis and infection, largely due to incomplete and erroneous evaluations. To fill this knowledge gap, we investigated the expression of signaling and trafficking proteins, and the in situ localization and transcriptome of naïve NKB cells comparied to conventionally-defined NK and B cells, as well as modulations of these cells in SIV infection. Intracellular signaling proteins and trafficking markers were expressed differentially on naïve NKB cells, with high expression of CD62L and Syk, and low expression of CD69, α4β7, FcRg, Zap70, and CD3z, findings which were more similar to B cells than NK cells. CD20
+ NKG2a/c+ NKB cells were identified in spleen, mesenteric lymph nodes (MLN), colon, jejunum, and liver of naïve rhesus macaques (RM) via tissue imaging, with NKB cell counts concentrated in spleen and MLN. For the first time, single cell RNA sequencing (scRNAseq), including BCR sequencing, of sorted NKB cells confirmed that NKB cells are unique. Transcriptomic analysis of naïve splenic NKB cells by scRNAseq showed that NKB cells undergo somatic hypermutation and express Ig receptors, similar to B cells. While only 15% of sorted NKB cells showed transcript expression of both KLRC1 (NKG2A) and MS4A1 (CD20) genes, only 5% of cells expressed KLRC1, MS4A1, and IgH/IgL transcripts. We observed expanded NKB frequencies in RM gut and buccal mucosa as early as 14 and 35 days post-SIV infection, respectively. Further, mucosal and peripheral NKB cells were associated with colorectal cytokine mileu and oral microbiome changes, respectively. Our studies indicate that NKB cells gated on CD3- CD14- CD20+ NKG2A/C+ cells were inclusive of transcriptomically conventional B and NK cells in addition to true NKB cells, confounding accurate phenotyping and frequency recordings that could only be resolved using genomic techniques. Although NKB cells were clearly elevated during SIV infection and associated with inflammatory changes during infection, further interrogation is necessary to acurately identify the true phenotype and significance of NKB cells in infection and inflammation. Author summary: Recently, our understanding of traditional innate immunity has become reshaped by the discovery of new innate immune cell subsets as well as newly identified functions/programming of previously described innate immune cell subsets. One such new and unique innate immune cell subset are the natural killer-like B (NKB) cells, which express both NK and B cell receptors. These cells have been described as first responder immune cells in infection and inflammation within mice, non-human primates (NHP), and humans. To clarify if the simple definition of CD3- NKG2A/C+ CD20+ cells as NKB cells is sufficient to truly identify the unique NKB cell phenotype, we characterized these cells via imaging cytometry and single cell RNA sequencing for the first time in an NHP model. Our data suggests that the NKB cell phenotype and transcriptome, while unique and relevant in SIV infection, remains very infrequent. Therefore, using flow cytometry to identify NKB cells based on the commonly accepted marker expression could be misleading and cause the erroneous classification of conventional NK cells and/or B cells as NKB cells. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
11. Translocated microbiome composition determines immunological outcome in treated HIV infection
- Author
-
Nganou-Makamdop, Krystelle, Talla, Aarthi, Sharma, Ashish Arunkumar, Darko, Sam, Ransier, Amy, Laboune, Farida, Chipman, Jeffrey G., Beilman, Gregory J., Hoskuldsson, Torfi, Fourati, Slim, Schmidt, Thomas E., Arumugam, Sahaana, Lima, Noemia S., Moon, Damee, Callisto, Samuel, Schoephoerster, Jordan, Tomalka, Jeffery, Mugyenyi, Peter, Ssali, Francis, Muloma, Proscovia, Ssengendo, Patrick, Leda, Ana R., Cheu, Ryan K., Flynn, Jacob K., Morou, Antigoni, Brunet-Ratnasingham, Elsa, Rodriguez, Benigno, Lederman, Michael M., Kaufmann, Daniel E., Klatt, Nichole R., Kityo, Cissy, Brenchley, Jason M., Schacker, Timothy W., Sekaly, Rafick P., and Douek, Daniel C.
- Published
- 2021
- Full Text
- View/download PDF
12. Effects of persistent modulation of intestinal microbiota on SIV/HIV vaccination in rhesus macaques
- Author
-
Klatt, Nichole R., Broedlow, Courtney, Osborn, Jessica M., Gustin, Andrew T., Dross, Sandra, O’Connor, Megan A., Coronado, Ernesto, Barnette, Philip, Hensley-McBain, Tiffany, Zevin, Alexander S., Muir, Roshell, Roederer, Alexander, Wangari, Solomon, Iwayama, Naoto, Ahrens, Chul Y., Smedley, Jeremy, Moats, Cassandra, Lynch, Rebecca M., Haddad, Elias K., Haigwood, Nancy L., Fuller, Deborah H., and Manuzak, Jennifer A.
- Published
- 2021
- Full Text
- View/download PDF
13. Probiotic supplementation reduces inflammatory profiles but does not prevent oral immune perturbations during SIV infection
- Author
-
Jones, Rhianna, Kroll, Kyle, Broedlow, Courtney, Schifanella, Luca, Smith, Scott, Hueber, Brady, Shah, Spandan V., Ram, Daniel R., Manickam, Cordelia, Varner, Valerie, Klatt, Nichole R., and Reeves, R. Keith
- Published
- 2021
- Full Text
- View/download PDF
14. Problematic Cannabis Use Is Associated with Reduced Rectal Microbial Species Richness and Diversity Among a Pilot Sample of Young Sexual and Gender Minorities.
- Author
-
Morgan, Ethan, Manuzak, Jennifer A., Broedlow, Courtney, Hudson, Hannah, D'Aquila, Richard, Carrico, Adam W., Klatt, Nichole R., and Mustanski, Brian
- Published
- 2024
- Full Text
- View/download PDF
15. PrEP awareness and use among reproductive age women in Miami, Florida.
- Author
-
Nogueira, Nicholas Fonseca, Luisi, Nicole, Salazar, Ana S., Cherenack, Emily M., Raccamarich, Patricia, Klatt, Nichole R., Jones, Deborah L., and Alcaide, Maria L.
- Subjects
SEXUAL intercourse ,GENITALIA infections ,HISPANIC American women ,EPIDEMICS ,BACTERIAL vaginitis ,HIV infections ,ENDOMETRIOSIS - Abstract
Background: Miami, Florida is an epicenter of the HIV epidemic in the US, with 20% of new HIV infections occurring in women. Despite effectiveness of Pre-Exposure Prophylaxis (PrEP) in preventing HIV, only 10% of eligible women benefit from its use. Setting: This study evaluates PrEP awareness and use, and factors associated with PrEP awareness among sexually active women in Miami, Florida. Methods: Results reported in this study included cross-sectional data that were collected as part of a baseline visit from a parent study. Cis-gender, HIV-negative, 18-45-year-old, sexually active women were recruited as part of a study evaluating recurrent bacterial vaginosis and HIV risk. Participants completed questionnaires assessing socio-demographics, HIV risk factors, prior history of HIV testing and reproductive tract infections, PrEP awareness and use. Relationships between variables and PrEP awareness were analyzed and multivariable logistic regression identified variables strongly associated with PrEP awareness. Results: Among the 295 women enrolled, median age was 31 (24–38) years, 49% Black, 39% White, and 34% Hispanic. Of 63% who knew about PrEP, only 5% were on PrEP. Women with income below poverty line (OR = 2.00[1.04,3.87];p = 0.04), more male sexual partners in past month (OR = 1.30[1.01,1.68];p = 0.04), lifetime HIV testing (OR = 6.42[2.83,14.52];p<0.01), and current bacterial vaginosis (OR = 2.28[1.18,4.40];p = 0.01) were more likely to be aware of PrEP. Lower odds of PrEP awareness were associated with being Black (OR = 0.38[0.15,0.96];p = 0.04), Hispanic (OR = 0.18[0.08,0.39];p<0.01), heterosexual (OR = 0.29[0.11,0.77];p<0.01), and reporting inconsistent condom use during vaginal sex (OR = 0.21[0.08,0.56];p<0.01). Conclusion: PrEP awareness is low among reproductive age women in a high-risk setting. Culturally tailored interventions are needed to increase PrEP awareness and uptake, especially among Black and Hispanic women with inconsistent condom use during vaginal sex with male partners. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial.
- Author
-
Boulware, David R, Murray, Thomas A, Proper, Jennifer L, Tignanelli, Christopher J, Buse, John B, Liebovitz, David M, Nicklas, Jacinda M, Cohen, Kenneth, Puskarich, Michael A, Belani, Hrishikesh K, Siegel, Lianne K, Klatt, Nichole R, Odde, David J, Karger, Amy B, Ingraham, Nicholas E, Hartman, Katrina M, Rao, Via, Hagen, Aubrey A, Patel, Barkha, and Fenno, Sarah L
- Subjects
IMMUNIZATION ,COVID-19 ,COVID-19 vaccines ,SEVERITY of illness index ,SECONDARY analysis - Abstract
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination has decreasing protection from acquiring any infection with emergence of new variants; however, vaccination continues to protect against progression to severe coronavirus disease 2019 (COVID-19). The impact of vaccination status on symptoms over time is less clear. Methods Within a randomized trial on early outpatient COVID-19 therapy testing metformin, ivermectin, and/or fluvoxamine, participants recorded symptoms daily for 14 days. Participants were given a paper symptom diary allowing them to circle the severity of 14 symptoms as none (0), mild (1), moderate (2), or severe (3). This is a secondary analysis of clinical trial data on symptom severity over time using generalized estimating equations comparing those unvaccinated, SARS-CoV-2 vaccinated with primary vaccine series only, or vaccine-boosted. Results The parent clinical trial prospectively enrolled 1323 participants, of whom 1062 (80%) prospectively recorded some daily symptom data. Of these, 480 (45%) were unvaccinated, 530 (50%) were vaccinated with primary series only, and 52 (5%) vaccine-boosted. Overall symptom severity was least for the vaccine-boosted group and most severe for unvaccinated at baseline and over the 14 days (P <.001). Individual symptoms were least severe in the vaccine-boosted group including cough, chills, fever, nausea, fatigue, myalgia, headache, and diarrhea, as well as smell and taste abnormalities. Results were consistent over Delta and Omicron variant time periods. Conclusions SARS-CoV-2 vaccine-boosted participants had the least severe symptoms during COVID-19, which abated the quickest over time. Clinical Trial Registration. NCT04510194. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Objective Identification of Cannabis Use Levels in Clinical Populations Is Critical for Detecting Pharmacological Outcomes.
- Author
-
Huang, Weize, Czuba, Lindsay C., Manuzak, Jennifer A., Martin, Jeffrey N., Hunt, Peter W., Klatt, Nichole R., and Isoherranen, Nina
- Published
- 2022
- Full Text
- View/download PDF
18. Infection with SARS-CoV-2 is associated with menstrual irregularities among women of reproductive age.
- Author
-
Cherenack, Emily M., Salazar, Ana S., Nogueira, Nicholas F., Raccamarich, Patricia, Rodriguez, Violeta J., Mantero, Alejandro M., Marsh, Allison, Gerard, Sophia, Maddalon, Marissa, Jones, Deborah L., Klatt, Nichole R., and Alcaide, Maria L.
- Subjects
MENSTRUATION ,CHILDBEARING age ,SARS-CoV-2 ,VACCINATION status ,FISHER exact test ,COVID-19 pandemic - Abstract
Background: Biological and psychological mechanisms may be responsible for menstrual irregularities occurring among women during the COVID-19 pandemic. Study design: From January 2019 to September 2021, women (18- to 45-years-old and not using hormonal contraception) were recruited in Miami-Dade County, Florida. Cross-sectional, self-report surveys collected data on menstrual irregularities, COVID-19 vaccination, stress, depression, and loneliness. A EUA approved rapid test assay using whole blood measured SARS-CoV-2 IgG antibodies. Chi-square and Fisher's exact tests described menstrual irregularities among women recruited before versus after the start of the COVID-19 pandemic and with detectable versus undetectable SARS-CoV-2 IgG antibodies. A logistic regression examined the relationship between the presence of SARS-CoV-2 IgG antibodies and menstrual irregularities controlling for age, stress, depression, and loneliness. Results: Among 182 women enrolled, 73 were enrolled after pandemic onset, and 36 provided vaccination data. Having detectable SARS-CoV-2 IgG antibodies was associated with a higher percentage of menstrual irregularities among unvaccinated women (0% vs. 39%, p =.026) and among all women regardless of vaccination status (31% vs. 5%; p =.005). Adjusting for age and psychological variables, the odds of menstrual irregularities were 7.03 times (95% CI [1.39, 35.60]; p =.019) higher among women with detectable antibodies compared to women without detectable antibodies. Neither enrollment date, age, nor psychological factors were associated to menstrual irregularities. Conclusions: Biological mechanisms related to SARS-CoV-2 infection may be responsible for irregular menstruation and should be further examined to mitigate the impact of the COVID-19 pandemic on women's health. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Through the Looking-Glass: Psychoneuroimmunology and the Microbiome-Gut-Brain Axis in the Modern Antiretroviral Therapy Era.
- Author
-
Carrico, Adam W., Cherenack, Emily M., Rubin, Leah H., McIntosh, Roger, Ghanooni, Delaram, Chavez, Jennifer V., Klatt, Nichole R., and Paul, Robert H.
- Published
- 2022
- Full Text
- View/download PDF
20. Altered Innate Immunity and Damaged Epithelial Integrity in Vaginal Microbial Dysbiosis.
- Author
-
Cheu, Ryan K., Mohammadi, Avid, Schifanella, Luca, Broedlow, Courtney, Driscoll, Connor B., Miller, Charlene J., Reeves, R. Keith, Yudin, Mark H., Hensley-McBain, Tiffany, Kaul, Rupert, and Klatt, Nichole R.
- Subjects
NATURAL immunity ,CO-cultures ,BACTERIAL vaginitis ,DYSBIOSIS ,GENITALIA ,NEUTROPHILS - Abstract
The role of neutrophils relative to vaginal dysbiosis is unclear. We hypothesize that bacterial vaginosis (BV)-associated bacteria may induce the activation and accumulation of mucosal neutrophils within the female reproductive tract (FRT), resulting in epithelial barrier damage. We collected endocervical cytobrushes from women with and without BV and assessed bacteria community type and frequency/functional phenotypes of neutrophils. We performed in vitro whole blood co-cultures with BV-associated bacteria and healthy vaginal commensals and assessed their impact on epithelial integrity using transepithelial electrical resistance. We demonstrated increased neutrophil frequency (p < 0.0001), activation (p < 0.0001), and prolonged lifespan (p < 0.0001) in the cytobrushes from women with non-Lactobacillus dominant (nLD) communities. Our in vitro co-cultures confirmed these results and identified significant barrier damage in the presence of neutrophils and G. vaginalis. Here, we demonstrate that BV-associated bacteria induce neutrophil activation and increase lifespan, potentially causing accumulation in the FRT and epithelial barrier damage. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms.
- Author
-
Bramante, Carolyn T, Proper, Jennifer L, Boulware, David R, Karger, Amy B, Murray, Thomas, Rao, Via, Hagen, Aubrey, Tignanelli, Christopher J, Puskarich, Michael, Cohen, Ken, Liebovitz, David M, Klatt, Nichole R, Broedlow, Courtney, Hartman, Katrina M, Nicklas, Jacinda, Ibrahim, Sherehan, Zaman, Adnin, Saveraid, Hanna, Belani, Hrishikesh, and Ingraham, Nicholas
- Subjects
SARS-CoV-2 ,VIRAL load ,CORONAVIRUS diseases ,COVID-19 ,VACCINATION status - Abstract
Background Data conflict on whether vaccination decreases severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load. The objective of this analysis was to compare baseline viral load and symptoms between vaccinated and unvaccinated adults enrolled in a randomized trial of outpatient coronavirus disease 2019 (COVID-19) treatment. Methods Baseline data from the first 433 sequential participants enrolling into the COVID-OUT trial were analyzed. Adults aged 30–85 with a body mass index (BMI) ≥25 kg/m
2 were eligible within 3 days of a positive SARS-CoV-2 test and <7 days of symptoms. Log10 polymerase chain reaction viral loads were normalized to human RNase P by vaccination status, by time from vaccination, and by symptoms. Results Two hundred seventy-four participants with known vaccination status contributed optional nasal swabs for viral load measurement: median age, 46 years; median (interquartile range) BMI 31.2 (27.4–36.4) kg/m2 . Overall, 159 (58%) were women, and 217 (80%) were White. The mean relative log10 viral load for those vaccinated <6 months from the date of enrollment was 0.11 (95% CI, –0.48 to 0.71), which was significantly lower than the unvaccinated group (P = .01). Those vaccinated ≥6 months before enrollment did not differ from the unvaccinated with respect to viral load (mean, 0.99; 95% CI, –0.41 to 2.40; P = .85). The vaccinated group had fewer moderate/severe symptoms of subjective fever, chills, myalgias, nausea, and diarrhea (all P < .05). Conclusions These data suggest that vaccination within 6 months of infection is associated with a lower viral load, and vaccination was associated with a lower likelihood of having systemic symptoms. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
22. A Summary of the Sixth International Workshop on Microbiome in HIV Pathogenesis, Prevention, and Treatment.
- Author
-
Sherrill-Mix, Scott, Yang, Michelle, Aldrovandi, Grace M., Brenchley, Jason M., Bushman, Frederic D., Collman, Ronald G., Dandekar, Satya, Klatt, Nichole R., Lagenaur, Laurel A., Landay, Alan L., Paredes, Roger, Tachedjian, Gilda, Turpin, Jim A., Serrano-Villar, Sergio, Lozupone, Catherine A., and Ghosh, Mimi
- Published
- 2022
- Full Text
- View/download PDF
23. Liver Bacterial Dysbiosis With Non-Tuberculosis Mycobacteria Occurs in SIV-Infected Macaques and Persists During Antiretroviral Therapy.
- Author
-
Fisher, Bridget S., Fancher, Katherine A., Gustin, Andrew T., Fisher, Cole, Wood, Matthew P., Gale Jr, Michael, Burwitz, Benjamin J., Smedley, Jeremy, Klatt, Nichole R., Derby, Nina, and Sodora, Donald L.
- Subjects
MYCOBACTERIA ,MACAQUES ,ANTIRETROVIRAL agents ,RHESUS monkeys ,DYSBIOSIS ,LIVER - Abstract
Liver disease is a significant contributor to morbidity and mortality in HIV-infected individuals, even during successful viral suppression with combination antiretroviral therapy (cART). Similar to HIV infection, SIV infection of rhesus macaques is associated with gut microbiome dysbiosis and microbial translocation that can be detected systemically in the blood. As microbes leaving the intestines must first pass through the liver via the portal vein, we evaluated the livers of both SIV-infected (SIV+) and SIV-infected cART treated (SIV+cART) rhesus macaques for evidence of microbial changes compared to uninfected macaques. Dysbiosis was observed in both the SIV+ and SIV+cART macaques, encompassing changes in the relative abundance of several genera, including a reduction in the levels of Lactobacillus and Staphylococcus. Most strikingly, we found an increase in the relative abundance and absolute quantity of bacteria within the Mycobacterium genus in both SIV+ and SIV+cART macaques. Multi-gene sequencing identified a species of atypical mycobacteria similar to the opportunistic pathogen M. smegmatis. Phosphatidyl inositol lipoarabinomannan (PILAM) (a glycolipid cell wall component found in atypical mycobacteria) stimulation in primary human hepatocytes resulted in an upregulation of inflammatory transcriptional responses, including an increase in the chemokines associated with neutrophil recruitment (CXCL1, CXCL5, and CXCL6). These studies provide key insights into SIV associated changes in hepatic microbial composition and indicate a link between microbial components and immune cell recruitment in SIV+ and SIV+cART treated macaques. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Metformin and Covid-19: Focused Review of Mechanisms and Current Literature Suggesting Benefit.
- Author
-
Ibrahim, Sherehan, Lowe, Jamie R., Bramante, Carolyn T., Shah, Surbhi, Klatt, Nichole R., Sherwood, Nancy, Aronne, Louis, Puskarich, Michael, Tamariz, Leonardo, Palacio, Ana, Bomberg, Eric, Usher, Michael, King, Samantha, Benson, Brad, Vojta, Deneen, Tignanelli, Chris, and Ingraham, Nicholas
- Subjects
COVID-19 ,COVID-19 pandemic ,METFORMIN ,TYPE 2 diabetes ,HEPATITIS C - Abstract
Metformin is the first-line medication for type 2 diabetes, but it also has a long history of improved outcomes in infectious diseases, such as influenza, hepatitis C, and in-vitro assays of zika. In the current Covid-19 pandemic, which has rapidly spread throughout the world, 4 observational studies have been published showing reduced mortality among individuals with home metformin use. There are several potential overlapping mechanisms by which metformin may reduce mortality from Covid-19. Metformin's past anti-infectious benefits have been both against the infectious agent directly, as well as by improving the underlying health of the human host. It is unknown if the lower mortality suggested by observational studies in patients infected with Covid-19 who are on home metformin is due to direct activity against the virus itself, improved host substrate, or both. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Syndemics and preexposure prophylaxis are independently associated with rectal immune dysregulation in sexual minority men.
- Author
-
Tapia, Gregory R., Glynn, Tiffany R., Miller, Charlene, Manuzak, Jennifer A., Broedlow, Courtney A., Mcgaugh, Angela, Cherenack, Emily M., Bauermeisterg, Jośe A., Grovh, Christian, Dilworthe, Samantha E., Parisii, Robert, Martinezi, Darling, Klattc, Nichole R., Carrico, Adam W., Bauermeister, José A, Grov, Christian, Dilworth, Samantha E, Parisi, Robert, Martinez, Darling, and Klatt, Nichole R
- Published
- 2021
- Full Text
- View/download PDF
26. Simian Immunodeficiency Virus Susceptibility, Immunology, and Microbiome in the Female Genital Tract of Adolescent Versus Adult Pigtail Macaques.
- Author
-
Berard, Alicia R., Miller, Charlene, Araínga, Mariluz, Broedlow, Courtney Ann, Noël-Romas, Laura, Schifanella, Luca, Hensley-McBain, Tiffany, Roederer, Alex, Driscoll, Connor B., Coronado, Ernesto, Manuzak, Jennifer, McKinnon, Lyle R., Villinger, Francois, Hope, Thomas J., Burgener, Adam D., and Klatt, Nichole R.
- Published
- 2021
- Full Text
- View/download PDF
27. Recurrent bacterial vaginosis following metronidazole treatment is associated with microbiota richness at diagnosis.
- Author
-
Gustin, Andrew T., Thurman, Andrea R., Chandra, Neelima, Schifanella, Luca, Alcaide, Maria, Fichorova, Raina, Doncel, Gustavo F., Gale, Michael, Klatt, Nichole R., and Gale, Michael Jr
- Subjects
BACTERIAL vaginitis ,SEXUALLY transmitted diseases ,METRONIDAZOLE ,MUCOUS membranes ,GENITALIA ,CELL adhesion ,ANTIBIOTICS ,BACTERIAL vaginitis diagnosis ,RESEARCH ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,VAGINA ,DISEASE relapse ,TREATMENT failure ,COMPARATIVE studies ,LACTOBACILLUS ,LONGITUDINAL method - Abstract
Background: Bacterial vaginosis-a condition defined by a shift from Lactobacillus dominance to a polymicrobial, anaerobic bacterial community-increases the risk of acquiring sexually transmitted infections and other complications of the female reproductive tract. Antibiotic treatment frequently fails to return the microbiome to an optimal Lactobacillus-dominated state. No criteria currently exist to identify the patients likely to experience treatment failure.Objective: We sought to identify the pretreatment community signatures associated with treatment failure through 16S ribosomal RNA gene analysis.Study Design: Twenty-eight women who were enrolled in an oral metronidazole treatment trial of bacterial vaginosis were studied. Cervicovaginal lavage samples were collected before metronidazole treatment and at 7 and 30 days posttreatment. Cervicovaginal lavage DNA was amplified and sequenced using a paired-end, V4 region 2×150 MiSeq run.Results: Of the 28 women, 25% failed to clear bacterial vaginosis; 35.7% demonstrated a transient clearance, shifting to community-type 2 (Lactobacillus iners dominant) at visit 2 only; 7.1% demonstrated a delayed clearance, reaching community-type 2 at the final visit only; and 32.1% of patients experienced sustained bacterial vaginosis clearance. Examination of the community composition and structure demonstrated that both the richness and the evenness were significantly lower for the women who experienced sustained clearance, whereas the women who failed to clear bacterial vaginosis possessed the highest median levels of richness, evenness, and diversity pretreatment. Soluble immune factors in the lower reproductive tract improved significantly following a shift from community-type 4 to a Lactobacillus-dominant microbiome, with the samples categorized as community-type 2 possessing significantly higher levels of secretory leukocyte protease inhibitor, growth-regulated alpha protein, and macrophage inflammatory protein-3 and significantly lower levels of intercellular adhesion molecule-1. Although the shifts to Lactobacillus dominance improved the markers of mucosal tissue health, these gains were only temporary among the women who experienced recurrence.Conclusion: Assemblies of highly diverse microbiota are associated with the enhanced resilience of bacterial vaginosis to standard metronidazole treatment. These communities may be foundational to treatment resistance or simply an indication of a well-established community made possible by canonical biofilm-forming taxa. Future studies must target the transcriptional activity of these communities under the pressure of antibiotic treatment to resolve the mechanisms of their resistance. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
28. Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
- Author
-
Bramante, Carolyn T, Buse, John B, Liebovitz, David M, Nicklas, Jacinda M, Puskarich, Michael A, Cohen, Ken, Belani, Hrishikesh K, Anderson, Blake J, Huling, Jared D, Tignanelli, Christopher J, Thompson, Jennifer L, Pullen, Matthew, Wirtz, Esteban Lemus, Siegel, Lianne K, Proper, Jennifer L, Odde, David J, Klatt, Nichole R, Sherwood, Nancy E, Lindberg, Sarah M, and Karger, Amy B
- Subjects
- *
CLINICAL trials , *COVID-19 treatment , *POST-acute COVID-19 syndrome , *COVID-19 pandemic , *DIAGNOSIS - Abstract
Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. We aimed to evaluate whether outpatient COVID-19 treatment with metformin, ivermectin, or fluvoxamine soon after SARS-CoV-2 infection could reduce the risk of long COVID. We conducted a decentralised, randomised, quadruple-blind, parallel-group, phase 3 trial (COVID-OUT) at six sites in the USA. We included adults aged 30–85 years with overweight or obesity who had COVID-19 symptoms for fewer than 7 days and a documented SARS-CoV-2 positive PCR or antigen test within 3 days before enrolment. Participants were randomly assigned via 2 × 3 parallel factorial randomisation (1:1:1:1:1:1) to receive metformin plus ivermectin, metformin plus fluvoxamine, metformin plus placebo, ivermectin plus placebo, fluvoxamine plus placebo, or placebo plus placebo. Participants, investigators, care providers, and outcomes assessors were masked to study group assignment. The primary outcome was severe COVID-19 by day 14, and those data have been published previously. Because the trial was delivered remotely nationwide, the a priori primary sample was a modified intention-to-treat sample, meaning that participants who did not receive any dose of study treatment were excluded. Long COVID diagnosis by a medical provider was a prespecified, long-term secondary outcome. This trial is complete and is registered with ClinicalTrials.gov , NCT04510194. Between Dec 30, 2020, and Jan 28, 2022, 6602 people were assessed for eligibility and 1431 were enrolled and randomly assigned. Of 1323 participants who received a dose of study treatment and were included in the modified intention-to-treat population, 1126 consented for long-term follow-up and completed at least one survey after the assessment for long COVID at day 180 (564 received metformin and 562 received matched placebo; a subset of participants in the metformin vs placebo trial were also randomly assigned to receive ivermectin or fluvoxamine). 1074 (95%) of 1126 participants completed at least 9 months of follow-up. 632 (56·1%) of 1126 participants were female and 494 (43·9%) were male; 44 (7·0%) of 632 women were pregnant. The median age was 45 years (IQR 37–54) and median BMI was 29·8 kg/m2 (IQR 27·0–34·2). Overall, 93 (8·3%) of 1126 participants reported receipt of a long COVID diagnosis by day 300. The cumulative incidence of long COVID by day 300 was 6·3% (95% CI 4·2–8·2) in participants who received metformin and 10·4% (7·8–12·9) in those who received identical metformin placebo (hazard ratio [HR] 0·59, 95% CI 0·39–0·89; p=0·012). The metformin beneficial effect was consistent across prespecified subgroups. When metformin was started within 3 days of symptom onset, the HR was 0·37 (95% CI 0·15–0·95). There was no effect on cumulative incidence of long COVID with ivermectin (HR 0·99, 95% CI 0·59–1·64) or fluvoxamine (1·36, 0·78–2·34) compared with placebo. Outpatient treatment with metformin reduced long COVID incidence by about 41%, with an absolute reduction of 4·1%, compared with placebo. Metformin has clinical benefits when used as outpatient treatment for COVID-19 and is globally available, low-cost, and safe. Parsemus Foundation; Rainwater Charitable Foundation; Fast Grants; UnitedHealth Group Foundation; National Institute of Diabetes, Digestive and Kidney Diseases; National Institutes of Health; and National Center for Advancing Translational Sciences. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Favorable Antiviral Effect of Metformin on Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of Coronavirus Disease 2019.
- Author
-
Bramante CT, Beckman KB, Mehta T, Karger AB, Odde DJ, Tignanelli CJ, Buse JB, Johnson DM, Watson RHB, Daniel JJ, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Siegel LK, Klatt NR, Anderson B, Hartman KM, Rao V, Hagen AA, Patel B, Fenno SL, Avula N, Reddy NV, Erickson SM, Fricton RD, Lee S, Griffiths G, Pullen MF, Thompson JL, Sherwood NE, Murray TA, Rose MR, Boulware DR, and Huling JD
- Abstract
Background: Metformin has antiviral activity against RNA viruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The mechanism appears to be suppression of protein translation via targeting the host mechanistic target of rapamycin pathway. In the COVID-OUT randomized trial for outpatient coronavirus disease 2019 (COVID-19), metformin reduced the odds of hospitalizations/death through 28 days by 58%, of emergency department visits/hospitalizations/death through 14 days by 42%, and of long COVID through 10 months by 42%., Methods: COVID-OUT was a 2 × 3 randomized, placebo-controlled, double-blind trial that assessed metformin, fluvoxamine, and ivermectin; 999 participants self-collected anterior nasal swabs on day 1 (n = 945), day 5 (n = 871), and day 10 (n = 775). Viral load was quantified using reverse-transcription quantitative polymerase chain reaction., Results: The mean SARS-CoV-2 viral load was reduced 3.6-fold with metformin relative to placebo (-0.56 log10 copies/mL; 95% confidence interval [CI], -1.05 to -.06; P = .027). Those who received metformin were less likely to have a detectable viral load than placebo at day 5 or day 10 (odds ratio [OR], 0.72; 95% CI, .55 to .94). Viral rebound, defined as a higher viral load at day 10 than day 5, was less frequent with metformin (3.28%) than placebo (5.95%; OR, 0.68; 95% CI, .36 to 1.29). The metformin effect was consistent across subgroups and increased over time. Neither ivermectin nor fluvoxamine showed effect over placebo., Conclusions: In this randomized, placebo-controlled trial of outpatient treatment of SARS-CoV-2, metformin significantly reduced SARS-CoV-2 viral load, which may explain the clinical benefits in this trial. Metformin is pleiotropic with other actions that are relevant to COVID-19 pathophysiology., Clinical Trials Registration: NCT04510194., Competing Interests: Potential conflicts of interest. J. B. B. reports contracted fees and travel support for contracted activities for consulting work paid to the University of North Carolina by Novo Nordisk; grant support by NIH, PCORI, Bayer, Boehringer-Ingelheim, Carmot, Corcept, Dexcom, Eli Lilly, Insulet, MannKind, Novo Nordisk, and vTv Therapeutics; personal compensation for consultation from Alkahest, Altimmune, Anji, Aqua Medical Inc, AstraZeneca, Boehringer-Ingelheim, CeQur, Corcept Therapeutics, Eli Lilly, embecta, GentiBio, Glyscend, Insulet, Mellitus Health, Metsera, Moderna, Novo Nordisk, Pendulum Therapeutics, Praetego, Stability Health, Tandem, Terns Inc, and Vertex.; personal compensation for expert testimony from Medtronic MiniMed; participation on advisory boards for Altimmune, AstraZeneca, and Insulet; a leadership role for the Association of Clinical and Translational Science; and stock/options in Glyscend, Mellitus Health, Pendulum Therapeutics, Praetego, and Stability Health. M. A. P. receives consulting fees from Opticyte and Cytovale. A. B. K. has served as an external consultant for Roche Diagnostics; received speaker honoraria from Siemens Healthcare Diagnostics, the American Kidney Fund, the National Kidney Foundation, the American Society of Nephrology, and Yale University Department of Laboratory Medicine; research support unrelated to this work from Siemens Healthcare Diagnostics, Kyowa Kirin Pharmaceutical Development, the Juvenile Diabetes Research Foundation, and the NIH; support for travel from College of American Pathologists Point-Of-Care Testing Committee; participation on an advisory board for the Minnesota Newborn Screening Advisory Committee; grants from NIH and JDRF for multiple unrelated clinical research projects and Kyowa Kirin Pharmaceutical Development and Siemens Healthcare Diagnostics for unrelated clinical research studies; and leadership roles for the American Board of Clinical Chemistry, Association for Diagnostics and Laboratory Medicine (ADLM) Evidence-Based Laboratory Medicine Subcommittee, and ADLM Academy Test Utilization Committee. M. R. R. reports consulting fees from 20/20 Gene Systems for coronavirus disease 2019 testing. D. B. R. reports grants from the NIH NCATS ACTIV-6 Steering Committee Chair. K. C. reports stock or stock options for United Health Group. C. T. B. reports consulting fees from NCATS/DCRI and the ACTIV-6 Executive Committee and support for travel from Academic Medical Education. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
30. Strategies used for the COVID-OUT decentralized trial of outpatient treatment of SARS-CoV-2.
- Author
-
Avula N, Kakach D, Tignanelli CJ, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Buse JB, Klatt NR, Anderson B, Karger AB, Hartman KM, Patel B, Fenno SL, Reddy NV, Erickson SM, Boulware DR, Murray TA, and Bramante CT
- Abstract
The COVID-19 pandemic accelerated the development of decentralized clinical trials (DCT). DCT's are an important and pragmatic method for assessing health outcomes yet comprise only a minority of clinical trials, and few published methodologies exist. In this report, we detail the operational components of COVID-OUT, a decentralized, multicenter, quadruple-blinded, randomized trial that rapidly delivered study drugs nation-wide. The trial examined three medications (metformin, ivermectin, and fluvoxamine) as outpatient treatment of SARS-CoV-2 for their effectiveness in preventing severe or long COVID-19. Decentralized strategies included HIPAA-compliant electronic screening and consenting, prepacking investigational product to accelerate delivery after randomization, and remotely confirming participant-reported outcomes. Of the 1417 individuals with the intention-to-treat sample, the remote nature of the study caused an additional 94 participants to not take any doses of study drug. Therefore, 1323 participants were in the modified intention-to-treat sample, which was the a priori primary study sample. Only 1.4% of participants were lost to follow-up. Decentralized strategies facilitated the successful completion of the COVID-OUT trial without any in-person contact by expediting intervention delivery, expanding trial access geographically, limiting contagion exposure, and making it easy for participants to complete follow-up visits. Remotely completed consent and follow-up facilitated enrollment., Competing Interests: The fluvoxamine placebo tablets were donated by the Apotex pharmacy. The ivermectin placebo and active tablets were donated by the Edenbridge pharmacy. The funders had no influence on the design or conduct of the trial and were not involved in data collection or analysis, writing of the manuscript, or decision to submit for publication. The authors assume responsibility for trial fidelity and the accuracy and completeness of the data and analyses., (© The Author(s) 2023.)
- Published
- 2023
- Full Text
- View/download PDF
31. Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial.
- Author
-
Bramante CT, Beckman KB, Mehta T, Karger AB, Odde DJ, Tignanelli CJ, Buse JB, Johnson DM, Watson RHB, Daniel JJ, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Siegel LK, Klatt NR, Anderson B, Hartman KM, Rao V, Hagen AA, Patel B, Fenno SL, Avula N, Reddy NV, Erickson SM, Fricton RD, Lee S, Griffiths G, Pullen MF, Thompson JL, Sherwood N, Murray TA, Rose MR, Boulware DR, and Huling JD
- Abstract
Current antiviral treatment options for SARS-CoV-2 infections are not available globally, cannot be used with many medications, and are limited to virus-specific targets.
1-3 Biophysical modeling of SARS-CoV-2 replication predicted that protein translation is an especially attractive target for antiviral therapy.4 Literature review identified metformin, widely known as a treatment for diabetes, as a potential suppressor of protein translation via targeting of the host mTor pathway.5 In vitro, metformin has antiviral activity against RNA viruses including SARS-CoV-2.6,7 In the COVID-OUT phase 3, randomized, placebo-controlled trial of outpatient treatment of COVID-19, metformin had a 42% reduction in ER visits/hospitalizations/death through 14 days; a 58% reduction in hospitalizations/death through 28 days, and a 42% reduction in Long COVID through 10 months.8,9 Here we show viral load analysis of specimens collected in the COVID-OUT trial that the mean SARS-CoV-2 viral load was reduced 3.6-fold with metformin relative to placebo (-0.56 log10 copies/mL; 95%CI, -1.05 to -0.06, p=0.027) while there was no virologic effect for ivermectin or fluvoxamine vs placebo. The metformin effect was consistent across subgroups and with emerging data.10,11 Our results demonstrate, consistent with model predictions, that a safe, widely available,12 well-tolerated, and inexpensive oral medication, metformin, can be repurposed to significantly reduce SARS-CoV-2 viral load.- Published
- 2023
- Full Text
- View/download PDF
32. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
- Author
-
Bramante CT, Huling JD, Tignanelli CJ, Buse JB, Liebovitz DM, Nicklas JM, Cohen K, Puskarich MA, Belani HK, Proper JL, Siegel LK, Klatt NR, Odde DJ, Luke DG, Anderson B, Karger AB, Ingraham NE, Hartman KM, Rao V, Hagen AA, Patel B, Fenno SL, Avula N, Reddy NV, Erickson SM, Lindberg S, Fricton R, Lee S, Zaman A, Saveraid HG, Tordsen WJ, Pullen MF, Biros M, Sherwood NE, Thompson JL, Boulware DR, and Murray TA
- Subjects
- Adult, Aged, Aged, 80 and over, COVID-19 Vaccines, Double-Blind Method, Female, Humans, Hypoxia etiology, Male, Middle Aged, Obesity complications, Overweight complications, Pregnancy, Pregnancy Complications, Infectious drug therapy, SARS-CoV-2, COVID-19 complications, Fluvoxamine therapeutic use, Ivermectin therapeutic use, Metformin therapeutic use, COVID-19 Drug Treatment
- Abstract
Background: Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an important component of the comprehensive response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic., Methods: In this phase 3, double-blind, randomized, placebo-controlled trial, we used a 2-by-3 factorial design to test the effectiveness of three repurposed drugs - metformin, ivermectin, and fluvoxamine - in preventing serious SARS-CoV-2 infection in nonhospitalized adults who had been enrolled within 3 days after a confirmed diagnosis of infection and less than 7 days after the onset of symptoms. The patients were between the ages of 30 and 85 years, and all had either overweight or obesity. The primary composite end point was hypoxemia (≤93% oxygen saturation on home oximetry), emergency department visit, hospitalization, or death. All analyses used controls who had undergone concurrent randomization and were adjusted for SARS-CoV-2 vaccination and receipt of other trial medications., Results: A total of 1431 patients underwent randomization; of these patients, 1323 were included in the primary analysis. The median age of the patients was 46 years; 56% were female (6% of whom were pregnant), and 52% had been vaccinated. The adjusted odds ratio for a primary event was 0.84 (95% confidence interval [CI], 0.66 to 1.09; P = 0.19) with metformin, 1.05 (95% CI, 0.76 to 1.45; P = 0.78) with ivermectin, and 0.94 (95% CI, 0.66 to 1.36; P = 0.75) with fluvoxamine. In prespecified secondary analyses, the adjusted odds ratio for emergency department visit, hospitalization, or death was 0.58 (95% CI, 0.35 to 0.94) with metformin, 1.39 (95% CI, 0.72 to 2.69) with ivermectin, and 1.17 (95% CI, 0.57 to 2.40) with fluvoxamine. The adjusted odds ratio for hospitalization or death was 0.47 (95% CI, 0.20 to 1.11) with metformin, 0.73 (95% CI, 0.19 to 2.77) with ivermectin, and 1.11 (95% CI, 0.33 to 3.76) with fluvoxamine., Conclusions: None of the three medications that were evaluated prevented the occurrence of hypoxemia, an emergency department visit, hospitalization, or death associated with Covid-19. (Funded by the Parsemus Foundation and others; COVID-OUT ClinicalTrials.gov number, NCT04510194.)., (Copyright © 2022 Massachusetts Medical Society.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.